2,378 Shares in Cencora, Inc. (NYSE:COR) Purchased by NorthRock Partners LLC

NorthRock Partners LLC acquired a new position in Cencora, Inc. (NYSE:COR) in the 4th quarter, Holdings Channel reports. The institutional investor acquired 2,378 shares of the company’s stock, valued at approximately $534,000.

Several other institutional investors have also bought and sold shares of the stock. Numerai GP LLC acquired a new stake in Cencora in the fourth quarter worth about $490,000. OMERS ADMINISTRATION Corp lifted its holdings in Cencora by 21.6% in the fourth quarter. OMERS ADMINISTRATION Corp now owns 7,192 shares of the company’s stock worth $1,616,000 after purchasing an additional 1,279 shares during the period. Obsidian Personal Planning Solutions LLC acquired a new stake in Cencora in the fourth quarter worth about $192,000. NDVR Inc. lifted its holdings in Cencora by 6.5% in the fourth quarter. NDVR Inc. now owns 1,327 shares of the company’s stock worth $298,000 after purchasing an additional 81 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Cencora by 10.1% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 45,933 shares of the company’s stock worth $10,320,000 after purchasing an additional 4,224 shares during the period. Institutional investors and hedge funds own 97.52% of the company’s stock.

Wall Street Analysts Forecast Growth

COR has been the subject of several research analyst reports. JPMorgan Chase & Co. upped their price objective on shares of Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. Evercore ISI upped their price target on shares of Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a report on Thursday, February 6th. Bank of America upped their price target on shares of Cencora from $270.00 to $285.00 and gave the company a “neutral” rating in a report on Friday, April 11th. UBS Group upped their price target on shares of Cencora from $298.00 to $335.00 and gave the company a “buy” rating in a report on Tuesday, April 29th. Finally, StockNews.com raised shares of Cencora from a “hold” rating to a “buy” rating in a report on Wednesday, March 12th. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, Cencora currently has a consensus rating of “Moderate Buy” and a consensus target price of $301.18.

Insiders Place Their Bets

In other news, Chairman Steven H. Collis sold 14,579 shares of the company’s stock in a transaction dated Tuesday, April 22nd. The stock was sold at an average price of $281.81, for a total value of $4,108,507.99. Following the transaction, the chairman now owns 315,913 shares in the company, valued at $89,027,442.53. This represents a 4.41% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Silvana Battaglia sold 5,000 shares of the company’s stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $242.24, for a total value of $1,211,200.00. Following the completion of the transaction, the executive vice president now owns 15,374 shares in the company, valued at $3,724,197.76. This represents a 24.54% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 50,223 shares of company stock worth $13,580,967. Company insiders own 10.80% of the company’s stock.

Cencora Price Performance

NYSE COR opened at $290.24 on Friday. The stock’s 50-day moving average price is $279.10 and its two-hundred day moving average price is $254.99. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. The company has a market cap of $56.28 billion, a PE ratio of 41.29, a PEG ratio of 1.31 and a beta of 0.60. Cencora, Inc. has a 1 year low of $214.77 and a 1 year high of $309.35.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.07 by $0.35. The firm had revenue of $75.50 billion for the quarter, compared to the consensus estimate of $75.41 billion. Cencora had a return on equity of 328.62% and a net margin of 0.46%. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.80 EPS. On average, analysts predict that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 2nd. Shareholders of record on Friday, May 16th will be issued a dividend of $0.55 per share. The ex-dividend date is Friday, May 16th. This represents a $2.20 annualized dividend and a yield of 0.76%. Cencora’s payout ratio is presently 25.52%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.